Our results support the notion that further activation of MAPK signaling through loss of inhibitors such as DUSP4 in melanoma cells that already harbor activating BRAF or NRAS mutations is detrimental, a hypothesis that will need to be explored with further experiments. The gene discussed is DUSP4; the disease is melanoma.